Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Zacks Investment Research

17 Jun 2026, 22:50 UTC · 2h ago

Adma Biologics (ADMA) Dips More Than Broader Market: What You Should Know

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

What the story claims

4 claims · each scored for market impact

What matters in this story

1
Adma Biologics currently holds a Zacks Rank of #5, which is the lowest possible rating indicating a 'Strong Sell'. — A Strong Sell rating from a quantitative model based on earnings estimate revisions typically signals negative short-term price momentum.
-0.60
2
The Zacks Consensus EPS estimate for Adma Biologics has decreased by 2.38% over the past month. — Downward revisions in earnings expectations generally lead to lower valuation and reduced investor confidence.
-0.40
3
Adma Biologics' forward P/E ratio of 10.46 is significantly discounted compared to the industry average of 21.05. — A lower P/E relative to peers can suggest the stock is undervalued, potentially attracting value investors.
+0.20
4